> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-179/
- Published: 2018-05-13T12:00:00.000Z
- Updated: 2026-09-15T00:04:42.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141423

[**FDA Panel To Review Cordis PMA Adverse Events**](https://www.fdaweb.com/fda-panel-to-review-cordis-pma-adverse-events/)  
*Federal Register* notice: FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee reviews a Cordis PMA for the Incraft AAA Stent Graft System. 05/11/2018

[**Guide on Outsourcing Facility Definition**](https://www.fdaweb.com/guide-on-outsourcing-facility-definition/)  
*Federal Register* notice: FDA makes available a guidance entitled “Facility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act.” 05/11/2018

[**Comments Sought on Biologic Samples Requests**](https://www.fdaweb.com/comments-sought-on-biologic-samples-requests/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for “Request for Samples and Protocols” (OMB Control Number 0910–0206). 05/11/2018

[**FDA Determines ANDA Eligibility for Sodium Iodide**](https://www.fdaweb.com/fda-determines-anda-eligibility-for-sodium-iodide/)  
*Federal Register* notice: FDA determines that GE Healthcare’s sodium iodide I 123 oral solution, 2 millicuries/milliliter was not withdrawn from sale due to safety or effectiveness. 05/11/2018

[**Guide on Toxicokinetics Q & A**](https://www.fdaweb.com/guide-on-toxicokinetics-q-a/)  
*Federal Register* notice. FDA makes available a guidance entitled “S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling — Questions and Answers.” 05/10/2018

[**Draft Guide on Urinary Tract Infections**](https://www.fdaweb.com/draft-guide-on-urinary-tract-infections/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment.” 05/10/2018

[**Comments Sought on Therapeutic Protein Drug-Drug Interactions**](https://www.fdaweb.com/comments-sought-on-therapeutic-protein-drug-drug-interactions/)  
*Federal Register* notice: FDA establishes a public docket to assist with its development of a policy/guidance document on assessing drug-drug interactions for therapeutic proteins. 05/09/2018

[**Draft Guide on Sec. 582 Waivers, Exceptions**](https://www.fdaweb.com/draft-guide-on-sec-582-waivers-exceptions/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act.” 05/09/2018

[**Heart Questionnaire Qualified for Device Developers**](https://www.fdaweb.com/heart-questionnaire-qualified-for-device-developers/)  
*Federal Register* notice: FDA qualifies the Minnesota Living with Heart Failure Questionnaire from the University of Minnesota as part of its Medical Device Development Tools program. 05/07/2018

[**FDA Corrects Docket Number on OMB Approval Notice**](https://www.fdaweb.com/fda-corrects-docket-number-on-omb-approval-notice/)  
*Federal Register* notice: FDA is correcting a 4/9 Federal Register notice about OMB approval of several information collection activities. 05/07/2018